biotech / news / / Medical Xpress
Rybrevant Faspro is approved across all indications of intravenously administered Rybrevant.
Rybrevant Faspro is the first subcutaneous therapy for EGFR-mutated NSCLC approved by the FDA.
KEY POINTS
- The treatment reduces administration time from several hours to five minutes compared to intravenous Rybrevant.
- Subcutaneous Rybrevant Faspro reduces administration-related reactions fivefold versus intravenous administration.
- Rybrevant Faspro showed a lower incidence of venous thromboembolism than intravenous Rybrevant in clinical trials.
- Rybrevant Faspro is now approved across all indications of intravenously administered Rybrevant.
COMPANIES
Summarized by Newsio from Medical Xpress. How we summarize →